StockData
LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW

Liminatus Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.11+0.07 (+2.30%)

Close on Oct 19, 2026

Market cap
$150.52M
P/E (TTM)
–
Dividend yield
–

SEC filings

30 of Liminatus Pharma's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 24, 2026Sep 29, 2026SEC EDGAR
Current report8-KAug 18, 2026Aug 18, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 14, 2026SEC EDGAR
Current report8-KAug 3, 2026Aug 4, 2026SEC EDGAR
Current report8-KJul 29, 2026Jul 30, 2026SEC EDGAR
Current report8-KJul 20, 2026Jul 24, 2026SEC EDGAR
Proxy statementDEF 14AAug 3, 2026Jul 13, 2026SEC EDGAR
Current report8-KJun 29, 2026Jul 6, 2026SEC EDGAR
Current report8-KJun 3, 2026Jun 3, 2026SEC EDGAR
Current report8-KMay 20, 2026May 27, 2026SEC EDGAR
Current report8-KMay 17, 2026May 20, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 15, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 31, 2026SEC EDGAR
Current report8-KFeb 27, 2026Mar 4, 2026SEC EDGAR
Current report8-KFeb 17, 2026Feb 18, 2026SEC EDGAR
Current report8-KFeb 6, 2026Feb 9, 2026SEC EDGAR
Current report8-KJan 15, 2026Jan 26, 2026SEC EDGAR
Current report8-KNov 19, 2025Nov 25, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 14, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Oct 6, 2025SEC EDGAR
Current report8-KAug 22, 2025Aug 25, 2025SEC EDGAR
Current report8-KAug 14, 2025Aug 14, 2025SEC EDGAR
Current report8-KJul 16, 2025Jul 17, 2025SEC EDGAR
Current report8-KJul 10, 2025Jul 11, 2025SEC EDGAR
Current report8-KJul 2, 2025Jul 3, 2025SEC EDGAR
Current report8-KJun 24, 2025Jun 24, 2025SEC EDGAR
Current report8-KJun 23, 2025Jun 24, 2025SEC EDGAR
Current report8-KMay 29, 2025Jun 4, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025Jun 2, 2025SEC EDGAR
Current report8-KApr 30, 2025May 6, 2025SEC EDGAR